Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Contraception. 2019 Jun 10;100(4):283–287. doi: 10.1016/j.contraception.2019.06.002

Figure 2.

Figure 2.

Steady-state and washout plasma concentration vs time profiles for LNG (A) and EE (B) in women taking ritonavir-boosted ARV regimens (COCs+ritonavir (RTV), n=5) compared to women taking ARV regimens not interacting with COCs or no ARV medication (COCs, n=10). Data are presented as mean ±SD.